(R)-N-(2-amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(4-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide

ID: ALA4547005

Chembl Id: CHEMBL4547005

PubChem CID: 155552430

Max Phase: Preclinical

Molecular Formula: C18H17F3N4O2S

Molecular Weight: 410.42

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  NC[C@@H](NC(=O)c1ccc(-c2ccc(C(F)(F)F)cc2)[nH]1)c1ncc(CO)s1

Standard InChI:  InChI=1S/C18H17F3N4O2S/c19-18(20,21)11-3-1-10(2-4-11)13-5-6-14(24-13)16(27)25-15(7-22)17-23-8-12(9-26)28-17/h1-6,8,15,24,26H,7,9,22H2,(H,25,27)/t15-/m1/s1

Standard InChI Key:  DZYJFGXCMUYKRB-OAHLLOKOSA-N

Alternative Forms

  1. Parent:

    ALA4547005

    ---

Associated Targets(Human)

TZM (838 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MT2 (2907 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Human immunodeficiency virus 1 (70413 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
env Envelope glycoprotein gp160 (755 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 410.42Molecular Weight (Monoisotopic): 410.1024AlogP: 3.08#Rotatable Bonds: 6
Polar Surface Area: 104.03Molecular Species: NEUTRALHBA: 5HBD: 4
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 5#RO5 Violations (Lipinski):
CX Acidic pKa: 13.67CX Basic pKa: 8.36CX LogP: 1.73CX LogD: 0.73
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.50Np Likeness Score: -0.91

References

1. Curreli F, Ahmed S, Benedict Victor SM, Iusupov IR, Belov DS, Markov PO, Kurkin AV, Altieri A, Debnath AK..  (2020)  Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.,  63  (4): [PMID:32031803] [10.1021/acs.jmedchem.9b02149]
2. Curreli F,Belov DS,Kwon YD,Ramesh R,Furimsky AM,O'Loughlin K,Byrge PC,Iyer LV,Mirsalis JC,Kurkin AV,Altieri A,Debnath AK.  (2018)  Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.,  154  [PMID:29860061] [10.1016/j.ejmech.2018.04.062]
3. Curreli F, Ahmed S, Benedict Victor SM, Iusupov IR, Spiridonov EA, Belov DS, Altieri A, Kurkin AV, Debnath AK..  (2021)  Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.,  32  [PMID:33461144] [10.1016/j.bmc.2021.116000]

Source